Pacific Edge on its NZ$36.1m equity capital raising
- Cameron Partners advised NZX/ASX listed Pacific Edge in relation to its NZ$36.1 million capital raising, comprising a NZ$25.4 million placement and a NZ$10.7 million retail offer
- The offer price of NZ$0.17 per share represented a 2.3% discount to the closing share price on 8 May 2026
- The placement and retail offer were oversubscribed and upsized, following strong support from New Zealand institutional and retail investors
- Pacific Edge develops and commercialises a suite of pioneering non-invasive genomic bladder cancer diagnostics tests (Cxbladder) for patients in the US, New Zealand and other global markets
- Pacific Edge recently received a draft Local Coverage Determination (LCD) establishing hematuria evaluation as a covered Medicare benefit, enabling its Cxbladder Triage and Triage Plus tests to qualify for Medicare reimbursement
